Zambon has secured a positive opinion from the Committee for Medicinal Products for Human Use for Hopledo, a modified-release formulation of levodopa and carbidopa formerly known as IPX203. The recommendation supports its use in adults with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilised with existing oral levodopa and dopa decarboxylase inhibitor regimens, although final European Commission authorisation is still required.
The regulatory milestone moves Hopledo closer to becoming a new oral option for patients whose symptom control has become increasingly dependent on frequent levodopa dosing. Its clinical and commercial significance, however, will depend on whether longer benefit from each dose translates into simpler treatment routines, acceptable tolerability and sufficiently meaningful improvements in daily function to justify switching from established and generally inexpensive therapies.
Why Hopledo’s regulatory progress matters beyond the arrival of another levodopa formulation
Hopledo does not introduce a new therapeutic molecule. Levodopa remains the most effective symptomatic treatment for Parkinson’s disease, while carbidopa reduces the peripheral conversion of levodopa before it reaches the brain. The innovation lies instead in how the established drugs are delivered and how long therapeutic levodopa concentrations may be maintained between doses.
The modified-release capsule combines immediate-release granules with extended-release beads. The immediate component is intended to raise levodopa levels rapidly, while the extended-release component uses sustained-release and mucoadhesive technologies designed to keep the formulation near the intestinal absorption region for longer. This dual approach attempts to address two persistent limitations of oral levodopa, its short plasma half-life and its narrow absorption window in the upper gastrointestinal tract.
That distinction matters because motor fluctuations often emerge as Parkinson’s disease progresses and the duration of benefit from individual levodopa doses becomes shorter. Patients may move between periods in which medication is working, commonly described as ON time, and periods in which symptoms return before the next scheduled dose, known as OFF time. Increasing dosing frequency can partly compensate, but it also creates complicated treatment schedules that are vulnerable to missed doses, meal-related absorption variability and inconsistent timing.
Hopledo therefore represents a formulation strategy rather than a change in the biological target. Its potential value is practical and pharmacokinetic: extending the useful effect of levodopa without immediately moving patients to more complex add-on combinations or device-assisted continuous infusion therapies. The unresolved question is whether this formulation advantage will produce enough improvement in everyday life to alter prescribing behaviour across diverse European healthcare systems.
How RISE-PD supports fewer daily doses without proving a dramatic overall efficacy gain
The positive opinion was primarily supported by RISE-PD, a randomised, double-blind, double-dummy Phase 3 trial comparing IPX203 with optimised immediate-release carbidopa and levodopa in patients already experiencing motor fluctuations. A total of 506 participants entered the randomised treatment period after open-label optimisation and conversion phases.
Participants receiving IPX203 took an average of three daily doses, compared with approximately five doses for those receiving the immediate-release formulation. IPX203 produced an average 0.53-hour improvement in daily Good ON time relative to immediate-release treatment, while Good ON time per dose was approximately 1.55 hours longer.
Those results support the argument that Hopledo can provide more sustained benefit from each administration. The per-dose advantage may be clinically relevant for patients whose daily routine is repeatedly interrupted by medication timing. Fewer dosing events may also reduce the risk that delays or missed doses trigger avoidable OFF periods.
The overall daily difference nevertheless requires measured interpretation. An additional 0.53 hours represents slightly more than half an hour of Good ON time across an entire day. The result was statistically significant, but it is less dramatic than the per-dose comparison may initially suggest. The study also found a reduction of approximately 0.48 hours in daily OFF time, while differences were not demonstrated on some broader motor rating scale measurements.
The trial consequently supports improved duration and dosing efficiency more strongly than a transformational improvement in overall motor function. Clinicians may view the reduction in treatment frequency as meaningful, particularly for patients taking levodopa five or more times each day, but the benefit will need to be assessed against individual symptom patterns, treatment goals and willingness to undergo dose conversion.
Why the trial design leaves unanswered questions about conversion and tolerability
RISE-PD included a three-week open-label period in which immediate-release levodopa and carbidopa treatment was optimised, followed by a four-week open-label conversion to IPX203. Only patients who reached a stable IPX203 regimen proceeded to the 13-week randomised comparison.
This structure strengthened the comparison by ensuring that both treatment regimens had been adjusted before randomisation. It also means that the randomised population may not fully represent every patient who begins conversion in routine clinical care. Of the 630 participants who entered the immediate-release adjustment phase, 589 entered IPX203 conversion and 506 progressed to randomisation.
Tolerability was particularly relevant during conversion. Treatment-emergent adverse events were reported by 38.9% of patients during the IPX203 conversion period, and 7.1% discontinued the study drug because of adverse events. Dyskinesia, nausea, dry mouth and dizziness were among the more frequently reported events.
During the randomised maintenance period, treatment-emergent adverse events occurred in 42.2% of patients receiving IPX203, compared with 31.6% receiving immediate-release treatment. Adverse events led to discontinuation in 5.5% of the IPX203 group and 1.2% of the immediate-release group. The European Medicines Agency has identified dyskinesia, nausea, dry mouth and dizziness among the most common side effects expected with Hopledo.
These findings do not negate the treatment’s benefit, but they underline the importance of careful dose conversion. Increasing the amount of levodopa delivered in each individual dose can extend symptom control while also increasing dopaminergic adverse effects if the regimen is not appropriately adjusted. The final European product information, conversion tables and recommended dosing intervals will therefore be central to real-world adoption.
Where Hopledo could fit among add-on drugs, older formulations and infusion therapies
European clinicians already have several strategies for managing levodopa wearing-off. These include increasing dose frequency, adding catechol-O-methyltransferase inhibitors such as opicapone or entacapone, using monoamine oxidase B inhibitors, adding dopamine agonists or considering device-assisted therapies for more advanced disease.
Hopledo could occupy a position between increasingly complex immediate-release schedules and escalation to multi-drug or infusion-based treatment. It may appeal most strongly to patients whose oral levodopa still works effectively but does not last long enough between doses. In these patients, improving the delivery profile of levodopa may be more intuitive than immediately adding another pharmacological mechanism.
The European market has previously authorised another extended-release carbidopa and levodopa capsule, Numient, but that product was never commercially introduced in the European Union and its authorisation was withdrawn in 2019 for commercial reasons. Hopledo is not entering an entirely novel scientific category, but it could establish a commercial presence in a segment where earlier extended-release capsule technology failed to gain traction.
Hopledo is also unlikely to replace continuous intestinal or subcutaneous levodopa delivery for patients whose disease can no longer be controlled with oral treatment. Continuous infusion therapies are designed for advanced Parkinson’s disease with severe fluctuations and provide a different level of treatment intensity. Hopledo may instead delay or simplify the pathway toward such therapies for selected patients, although that possibility has not been definitively established.
Competition will also be influenced by cost. Immediate-release levodopa and carbidopa products are widely available and relatively inexpensive. Add-on drugs may already be familiar to neurologists and reimbursement authorities. Hopledo will need to demonstrate that reduced dosing frequency and improved symptom stability justify its price, particularly where budget holders demand evidence of reduced caregiver burden, improved adherence or fewer healthcare interventions.
Why Zambon’s Parkinson’s footprint may support adoption without guaranteeing access
Zambon licensed European Union, United Kingdom and Swiss rights to IPX203 from Amneal Pharmaceuticals in 2024. The agreement places commercial responsibility with a pharmaceutical group that already has a European neurology presence and experience marketing safinamide as an add-on treatment for fluctuating Parkinson’s disease.
That existing infrastructure may help Zambon identify movement disorder specialists, educate prescribers on conversion and integrate Hopledo into established Parkinson’s treatment pathways. The product also complements the group’s strategy of expanding beyond traditional therapeutic areas into central nervous system and rare disease medicines.
Amneal Pharmaceuticals already markets IPX203 in the United States as Crexont following approval in August 2024. United States performance provides early evidence that the formulation can gain commercial acceptance. Amneal reported $21 million in Crexont revenue during the first quarter of 2026 and identified the product as a contributor to growth in its specialty medicines business.
European uptake cannot be assumed from United States performance. Pricing, reimbursement and prescribing decisions are fragmented across individual European markets. Some countries may grant relatively rapid access, while others could require additional health technology assessment, budget impact modelling or negotiations before broad reimbursement begins.
Zambon expects a phased European introduction beginning in October 2026, subject to European Commission approval. That timetable appears feasible under the centralised authorisation process, but commercial availability will still vary by country. The first launch markets may therefore provide an important test of physician willingness to switch patients from optimised immediate-release treatment and of payer acceptance of the formulation’s value proposition.
What regulators and clinicians will watch after the European Commission decision
The European Commission generally issues the legally binding decision following a positive CHMP recommendation. Once authorisation is granted, attention will move from regulatory probability to implementation details.
The final summary of product characteristics will clarify the approved strengths, conversion approach, dosing limitations, food-related instructions, contraindications and management of adverse reactions. The European Medicines Agency has indicated that Hopledo is expected to be available in four modified-release capsule strengths, giving clinicians some flexibility while potentially adding complexity during titration.
Prescribers will also want evidence on treatment persistence outside a controlled study. Real-world patients may be older, cognitively impaired, medically complex or less able to complete symptom diaries and tightly timed titration schedules than participants in RISE-PD. The pivotal trial excluded several groups, including patients with recent psychosis histories and those receiving certain Parkinson’s treatments, limiting how confidently its findings can be generalised.
Zambon is attempting to address some of these questions through the Phase 3b ADIP study. The European trial is evaluating IPX203 against immediate-release levodopa and carbidopa in advanced Parkinson’s disease using more personalised dosing intervals. The study is expected to enrol 92 participants and includes an optional extension period.
ADIP is relevant because RISE-PD did not permit IPX203 administration more frequently than every six hours, even though some participants continued to experience considerable OFF time. More flexible dosing may improve symptom control for certain patients. However, ADIP is open-label and relatively small, which limits its ability to provide definitive comparative evidence.
Hopledo’s value will depend more on implementation than headline efficacy
The positive CHMP opinion supports Hopledo as a credible addition to the European Parkinson’s treatment landscape. Its strongest proposition is not that it replaces levodopa, but that it may make levodopa work more consistently and with fewer administrations for patients whose existing oral regimen has become difficult to manage.
The pivotal data show a clear pharmacological and dosing-duration benefit. They also reveal a more modest average improvement across the full day, higher adverse-event rates during conversion and unresolved questions about flexible dosing, long-term persistence and comparative value against established add-on therapies.
Hopledo may prove most useful for a defined group of patients who continue to respond well to levodopa but experience predictable wearing-off and burdensome dosing schedules. Successful adoption will require neurologists to identify those patients accurately, manage conversion carefully and set realistic expectations regarding the scale of benefit.
For Zambon, European approval would validate its licensing strategy and deepen its position in Parkinson’s disease. For clinicians, the product offers another step in the treatment ladder before more invasive or operationally demanding therapies are considered. The remaining test is whether that additional step becomes routine clinical practice or remains a specialised option for selected movement disorder centres.
